NiKang Therapeutics

An early stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs

News and Events

June 10, 2021 - NiKang Therapeutics Appoints Robert Xin, M.D., Ph.D., as Chief Medical Officer Read More

May 26, 2021 - NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets Read More

April 5, 2021 - NiKang Therapeutics Appoints Kelsey Chen, Ph.D., MBA, as Chief Financial Officer Read More

January 28, 2021 - NiKang Therapeutics Appoints Gary Yeung, CFA, to Board of Directors Read More

January 6, 2021 - Erasca announced the dosing of a first patient in December 2020 in Erasca’s FLAGSHP-1 study, a Phase 1/1b clinical trial to evaluate ERAS-601, a SHP2 inhibitor discovered and developed by NiKang Therapeutics Read More

September 14, 2020 - NiKang Therapeutics Completes $50 Million Series B Financing Read More

April 23, 2020 - Hansoh Pharma and NiKang Therapeutics Enter into a Development and Commercialization Partnership for a Novel Treatment for Anti-Viral Diseases in China Read More